AP NEWS

Psoriasis

Amgen to spend $13.4B on Celgene psoriasis drug Otezla

By The Associated PressAugust 26, 2019

Celgene will unload the psoriasis treatment Otezla for $13.4 billion to help make its acquisition by fellow drugmaker Bristol-Myers pass regulatory muster.

Novartis 1Q profit jumps 12 percent as heart drug sales soar

April 19, 2018

GENEVA (AP) — Swiss pharmaceuticals company Novartis says net income jumped 12 percent in the first quarter, pointing to explosive growth in its heart-failure drug Entresto as its rollout continues, and powerful double-digit percentage growth for psoriasis drug Cosentyx.

FDA OKs new Johnson & Johnson treatment for psoriasis

By LINDA A. JOHNSONJuly 13, 2017

TRENTON, N.J. (AP) — U.S. regulators approved a new psoriasis drug from Johnson & Johnson Thursday, giving people with the itchy and painful condition another treatment option.

Johnson & Johnson said that in one patient study, about seven in 10 patients getting the drug, Tremfya, had clear or nearly clear skin after 24 weeks of treatment. That compares with about four in 10 patients receiving rival AbbVie's Humira, which treats several immune disorders and is the world's top selling drug.

Novartis profit slips as key drug goes generic

October 25, 2016

FRANKFURT, Germany (AP) — Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.

Core net income fell 2 percent to $2.94 billion from $2.99 billion in the previous-year quarter. The loss of Gleevec, used to treat chronic myeloid leukemia, to generic use hurt sales revenue.

Press Releases
  1. PR NewswireBimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis StudyNovember 15, 2019
  2. Business WireHCPLive® Launches ‘Advances in the Management of Plaque Psoriasis’ Video SeriesNovember 13, 2019
  3. PR NewswireJanssen Presents New Four-Year TREMFYA® (guselkumab) Data Demonstrating Maintained Rates of Skin Clearance in Adult Patients with Moderate to Severe Plaque PsoriasisOctober 18, 2019
  4. Business WireSamsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) CongressOctober 9, 2019
  5. Globe NewswireEvelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b TrialAugust 6, 2019
More Press Releases
AP's Member Network:
  1. Watertown Daily TimesPsoriasis: The importance of connectionOctober 17, 2019
All contents © copyright 2019 The Associated Press. All rights reserved.